Iterum Therapeutics plc filings document the company’s anti-infective business, ORLYNVAH™ commercialization disclosures, capital structure, governance votes, and corporate-status events. Recent Form 8-K reports cover financial results, at-the-market ordinary share offerings under a Form S-3 registration statement, shareholder votes on authorized share capital, allotment authority, pre-emption rights, and a reverse share split.
The filing record also documents Nasdaq continued-listing and delisting matters, the Irish winding-up petition, the appointment of joint provisional liquidators, and default implications for the company’s limited recourse royalty-linked subordinated notes. These disclosures frame Iterum’s formal record around liquidity, listing status, shareholder authorization limits, debt obligations, and the provisional liquidation process.
Iterum Therapeutics plc filed a prospectus supplement to sell up to $20,000,000 of ordinary shares in an at-the-market program through H.C. Wainwright & Co., not to exceed 21,756,057 ordinary shares. Sales may be made on the Nasdaq Capital Market or by other permitted methods, with Wainwright acting as sales agent.
The program is limited to the company’s authorized but unissued share capacity. Based on 21,756,057 shares currently available for issuance and an assumed price of $0.7377, the company indicates it could sell up to approximately $16,049,443 under the agreement. Iterum will pay a 3.0% sales commission to Wainwright and would receive the net proceeds.
This supplement supersedes the prior ATM supplement, moving the remaining $4,775,345 capacity under that document into this one. Iterum reports aggregate gross proceeds of approximately $36.2 million previously raised under the sales agreement. Ordinary shares outstanding were 48,051,157 as of September 15, 2025. The shares trade on Nasdaq as “ITRM.”
Iterum Therapeutics plc reported the results of its 2025 annual general meeting. Shareholders elected David Kelly as a Class I director, with 10,795,342 votes for, 2,848,953 against and 665,812 abstentions, and ratified KPMG as independent registered public accounting firm for the fiscal year ended December 31, 2025, with 17,986,081 votes for and 3,759,990 against.
However, shareholders did not approve several key proposals. The advisory vote on executive compensation failed, with 5,406,944 votes for and 8,449,597 against. Proposals to increase authorized share capital, grant updated authority to allot and issue securities, opt out of pre-emption rights under Irish law, and add 4,000,000 shares to the equity incentive plan were all rejected by wide margins, limiting the board’s flexibility to issue new shares or expand equity-based compensation.
Iterum Therapeutics plc reported receiving a Nasdaq notice on August 25, 2025 stating that its ordinary shares no longer meet the exchange’s minimum bid price requirement. The company fell out of compliance with Nasdaq Listing Rule 5550(a)(2), which requires a closing bid price of at least $1.00 per share based on the last 30 consecutive business days.
The notice does not immediately remove Iterum’s shares from The Nasdaq Capital Market. The company has 180 calendar days, until February 23, 2026, for its closing bid price to reach at least $1.00 for a minimum of 10 consecutive business days to regain compliance. If it fails to do so, Iterum may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially including a reverse share split.
Nasdaq could ultimately move to delist the shares if compliance is not restored, though Iterum could appeal any such decision. The company plans to monitor its share price and consider available options but acknowledges there is no assurance it will regain compliance or avoid delisting.
Iterum Therapeutics plc has begun the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The drug is intended to treat adult women with uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis who have limited or no alternative oral antibacterial options. The launch marks Iterum’s move from development to commercial availability for this product in the United States.
Michael W. Dunne, a director of Iterum Therapeutics plc (ITRM), filed a Form 4 reporting a transaction on 08/08/2025. The filing shows a reported acquisition of 15,000 ordinary shares at $0.7236. Following the transaction, Mr. Dunne beneficially owned 235,001 shares on a direct basis. The Form 4 bears his signature dated 08/12/2025.